Idera Pharmaceuticals (Nasdaq: IDRA) announced that it presented new data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments increased antitumor activity in preclinical models of lymphoma. The presentation by Idera scientists, entitled �IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, rituximab and cytotoxics in preclinical models of hematological malignancies�, abstract number 3724, was made at the 53rd annual meeting of the American Society for Hematology being held in San Diego, California December 11-13, 2011.
�The data presented show that IMO-4200 provides a novel scientific rationale for the targeted immunotherapy of hematological malignancies,� said Nicola La Monica, Ph.D., VP of Biology of Idera Pharmaceuticals. �IMO-4200 has shown to potentiate the anti-cancer activity of a broad range of approved agents, including rituximab, bortezomib and ofatumumab, in preclinical models of lymphoma.�
IMO-4200 is a novel synthetic RNA-based dual agonist of TLR7 and TLR8 identified as a lead drug candidate for the treatment of hematological malignancies. IMO-4200 is designed to stimulate immune responses mediated through TLR7 and TLR8, which are expressed in human dendritic cells, B-cells, monocytes, and macrophages. In preclinical mouse models of cancer, IMO-4200 has shown anticancer activity involving both innate and adaptive immune responses. IMO-4200, when administered in combination with approved cancer therapy drugs, rituximab, ofatumumab or bortezomib, showed significantly increased antitumor activity compared to the single-agent effects in several preclinical lymphoma models.
Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The Company’s TLR-targeted candidates are being developed to treat aut! oimmune and inflammatory diseases, cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes.
More about IDRA at www.iderapharma.com.
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) announced participation in a Phase 2/3 randomized, controlled, multicenter trial evaluating novel treatment regimens against low dose cytarabine (LD Ara-C), a commonly used treatment of elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This trial, known as the Less Intensive 1 (LI-1) Study, is being conducted by the United Kingdom’s National Cancer Research Institute (NCRI) Haematological Oncology Study Group under the direction of Professor Alan K. Burnett, Head of Haematology, Department of Medical Genetics, Haematology & Pathology at Cardiff University School of Medicine. Two regimens containing Sunesis’ lead drug candidate, vosaroxin, have been selected as investigational treatment arms in this study.
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.
Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), announced interim results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma patients. The data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011 in San Diego, CA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclon! al antib ody-based therapies for the treatment of cancer.
Cleantech Transit, Inc. (CLNO)
Cleantech Transit, Inc. is in the business of producing and conserving power. Cleantech Transit produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit’s goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy. Cleantech Transit, Inc. was founded in 2006 and is based in Scottsdale, Arizona.
There multiple ways to use biomass to create energy:
When plant matter is heated (but not burned), it breaks down into various forms such as gases, liquids and solids. These can be processed and refined into useful fuels. These fuels can either be burned in gas turbines to create electricity, or be stored in fuel cells and later used to create electricity when necessary. The advantage of this process is that very few emissions are created - and at times none.
By using biochemical methods, equivalent to fermentation, it’s possible to convert biomass into a combustible fuel. This fuel can be burned to create power and heat.
Biomass oil, such as soybean and canola oil can be chemically converted to liquid fuel that can be used to create “biodiesel” fuel for trucks.
Biomass can also be used to create compost, which is decayed plant or food products mixed together in a pile and spread out to help plants grow.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of th! e Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
For more information please visit official website of CLNO: www.cleantechtransit.com
Span-America Medical Systems, Inc. (NASDAQ:SPAN) announced that it has acquired substantially all the assets of M.C. Healthcare Products Inc. (MCHP). MCHP, located in Beamsville, Ontario, Canada, is a privately-owned manufacturer and marketer of medical bed frames and related products for the long term care market.
Span-America manufactures and markets a comprehensive selection of pressure management products for the medical market, including Geo-Matt�, PressureGuard�, Geo-Mattress�, Custom Care�, Span+Aids�, Isch-Dish�, Risk Manager� and Selan� products.
Related Articles:Here's How Oshkosh May Be Failing You
Variety Of Classroom Books
Tags: Hot Stocks To Buy ,Hot Stocks To Buy For 2015 ,Hot Stocks To Invest In ,Hot Value Stocks ,LFQ ,NYSE ,OSK ,Top Dividend Stocks 2012
No comments:
Post a Comment